Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns

On Tuesday, Roth Capital revised its price target for Bio-Path Holdings Inc. (OTC:BPTH) to $2 from $9, while keeping a Buy rating on the shares. This adjustment came after the company provided an update on its clinical pipeline progress.

A scientist in a lab coat mixing the chemicals for the Liposomal Bcl-2 drug development.

In positive clinical developments, Bio-Path’s Prexigebersen achieved two complete responses in its Phase 2 trial for Acute Myeloid Leukemia/AML. This demonstrated continued treatment durability with over 15 treatment cycles and sustained complete remission. For its Phase 1 BP0012 trial, a patient in cohort 3 showed a 50% reduction of blast cells, which then led to enrollment in cohort 4.

Additionally, the Phase 1/1b clinical trial of BP1001-A in advanced solid tumors is progressing, with one patient in the second dose cohort showing a 15% reduction in her primary tumor. Preclinical studies for BP1001-A as a potential treatment for obesity in Type 2 Diabetes patients have also shown promise, with an IND application expected in 2025.

Bio-Path Holdings Inc. (OTC:BPTH) is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company in the US.

While we acknowledge the potential of BPTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BPTH and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.